Physician profile

Hisham Wehbe

Cleveland, OH

NPI 1679182588

$527.92

in general payments reported to CMS, 2019-2025

7 companies · $303 in 2025

The $303 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$527.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $146.81 2025 Uplizna
Myriad Genetic Laboratories, INC. $124.85 2025 Myrisk
Medtronic, INC. $109.76 2024 Gi Genius
Genzyme Corporation $90.16 2024
Takeda Pharmaceuticals U.S.A., INC. $25.09 2024 Entyvio
Abbvie INC. $16.37 2025
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.88 2025 Xifaxan

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hisham Wehbe

$527.92

in general payments reported 2019-2025

Years
2024-2025
Top company
Amgen INC.
Context
The $303 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11684449/hisham-wehbe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.